JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: NLG919 analog (RG6078 analog; GDC-0919 analog; GDC0919 analog; IDO-IN-7; NLG-919 analog) is a novel, potent and orally bioavailable inhibitor of IDO (indoleamine-(2, 3)-dioxygenase) pathway with potential immunomodulating and antitumor activity. It inhibits IDO1 with Ki/EC50 of 7 nM/75 nM in cell-free assays. IDO1 catalyzes the conversion of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, NLG919 analog increases tryptophan levels, restores the proliferation and activation of immune cells (e.g. NK cells, T-lymphocytes), leading to a reduction in tumor-associated regulatory T-cells.
References: J Immunother Cancer. 2014 Jul 7; 2:21; AACR; Cancer Res 2013; 73(8 Suppl):Abstract nr 491.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!